DRUG DISCOVERY WORKFLOWS

Drug discovery

An evidence-driven path across target validation, screening, efficacy assessment and research support.

Request workflow guidance

WORKFLOW MAP

From sample to evidence

01

Target validation

Combine genetics, protein interaction, binding and cellular mechanism evidence to assess target feasibility.

  1. Disease-association evidence
  2. Expression and localization
  3. Direct binding or occupancy
  4. Cellular mechanism

RisksAssociation is not causation, model mismatch and missing independent validation.

QCControls, orthogonal methods, dose relationship and independent models.

02

Compound screening

Use high-throughput, phenotypic or virtual screens, then cascade assays to remove false positives.

  1. Plan library and plate layout
  2. Run primary screen
  3. Confirm and dose-response
  4. Check binding and selectivity

RisksPlate effects, assay interference, false positives and weak repeat hits.

QCZ' factor, plate drift, hit rate, repeatability and orthogonal readouts.

03

Efficacy assessment

Evaluate potency, selectivity, mechanism and resistance risk in cell, organoid or animal models.

  1. Define model and endpoint
  2. Design dose and time
  3. Read phenotype and mechanism
  4. Analyze effect and replicates

RisksModel extrapolation, insufficient exposure, toxicity confounding and low power.

QCEC50/IC50, exposure, viability, mechanism markers and independent repeats.

04

Research support

Connect data analysis, sample management, method development and review for continuous candidate progression.

  1. Register data and samples
  2. Lock methods and parameters
  3. Review results
  4. Design the next decision cycle

RisksVersion confusion, irreproducibility and unclear decision boundaries.

QCData lineage, versions, audit trails, review sign-off and decision records.

RESEARCH UPDATES

Recent research and workflow evidence